Choosing the right TKI for chronic myeloid leukemia: when the truth lies in "long-term" safety and efficacy
- PMID: 21674581
- DOI: 10.1002/ajh.22084
Choosing the right TKI for chronic myeloid leukemia: when the truth lies in "long-term" safety and efficacy
Comment on
-
Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.Am J Hematol. 2011 Jul;86(7):533-9. doi: 10.1002/ajh.22037. Epub 2011 Apr 27. Am J Hematol. 2011. PMID: 21538470 Clinical Trial.
-
Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia.Am J Hematol. 2011 Jul;86(7):610-1. doi: 10.1002/ajh.22051. Epub 2011 May 31. Am J Hematol. 2011. PMID: 21630307 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical